Elderberry juice rich in anthocyanins boosts glucose regulation and fat metabolism, with significant effects on gut ...
Maridebart cafraglutide, a novel injectable GLP-1 receptor agonist/GIP receptor antagonist, reduced body weight by up to ...
Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...
New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...
A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...
For the first time in a decade, U.S. obesity rates have begun to decline, raising hopes that the nation may be turning a ...
Weight-loss treatments are on the cusp of a revolution, and could benefit large numbers of Indians after the main patent ...
In a surprising turn, obesity rates in the United States have decreased for the first time in more than a decade, according to a study published in the Journal of JAMA Health Forum. The study ...
The history of breakthrough weight loss medicines is riddled with tragic results. Based on the histories of phen-fen and rimonabant, many are concerned about GLP-1 agonists. Notably, the mechanisms of ...
In a first, scientists at the World Health Organisation (WHO) have endorsed a new class of medicines known ... doctors prescribed it off-label for obesity, sparking a social media frenzy and supply ...
Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of becoming the company’s next blockbuster weight loss drug. RFK Jr. hit an ...
Novo’s latest setback centers on CagriSema, a next-generation obesity treatment combining two drugs, which was meant to outshine Lilly’s Zepbound. The drug helped people lose 22.7% of their ...